Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769562 | 0.76 | GABRG2 (0.58) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2657570 | 0.72 | GABRG2 (0.53) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL7001291 | 0.72 | GABRG2 (0.45) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2657377 | 0.71 | CASP1 (0.38) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL340744 | 0.70 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2658689 | 0.69 | GABRG2 (0.49) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2658287 | 0.68 | GABRG2 (0.47) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2659908 | 0.68 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2183283 | 0.67 | GABRG2 (0.83) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2659419 | 0.67 | GABRG2 (0.45) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593325-B1 | Method for the treatment of anxiety which comprises administering to a patient in need of such treatment an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof. | MERCK SHARP & DOHME LTD. (GB) | 2003-07-15 | — | — | US | disclosed |